| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000022974 |
| Receipt No. | R000026301 |
| Official scientific title of the study | Effects of a Food Containing Mushroom Mycelium Powder on Temporal or Long-Term Fatigue by Physical Labour, Quality of Sleep, and Vitality. |
| Date of disclosure of the study information | 2016/07/01 |
| Last modified on | 2017/02/09 (Ver. 3) |
| Basic information | ||
| Official scientific title of the study | Effects of a Food Containing Mushroom Mycelium Powder on Temporal or Long-Term Fatigue by Physical Labour, Quality of Sleep, and Vitality. | |
| Title of the study (Brief title) | Effects of a Food Containing Mushroom Mycelium Powder on Temporal or Long-Term Fatigue by Physical Labour, Quality of Sleep, and Vitality. | |
| Region |
|
|
| Condition | ||
| Condition | Healthy adults feeling tired by work | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | This study examines effects of a food containing mushroom mycelium powder on temporal of long-term fatigue by physical labour, quality of sleep, and vitality. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | [Fatigue and vitality]
(1)CFS (Chalder's Fatigue Scale) (Week 0, 1, 4, 8, 12) (2)Japanese Edition of Profile of Mood States (Week 0, 1, 4, 8, 12) [Sleep] (1)Pittsburgh Sleep Quality Index, Japanese Version (Week 0, 4, 8, 12) (2)Obstructive Sleep Apnea Questionnaire (Week 0, 1) |
| Key secondary outcomes | [Antioxidant]
(1)Diacron-Reactive Oxygen Metabolites test (Week 0, 1, 4, 8, 12) (2)Biological Antioxidant Potential test (Week 0, 1, 4, 8, 12) (3)Blood thiobarbituric acid reactive substances (Week 0, 1, 4, 8, 12) (4)Urinary isoprostane (Week 0, 4, 8, 12) (5)Urinary 8-OHdG (Week 0, 4, 8, 12) [Safety] (1)Blood pressure, pulsation (Week 0, 1, 4, 8, 12) (2)Weight, body fat percentage, BMI (Week 0, 1, 4, 8, 12) (3)Hematologic test (Week 0, 4, 8, 12) (4)Blood biochemical test (Week 0, 4, 8, 12) (5)Urine analysis (Week 0, 4, 8, 12) (6)Doctor's questions (Week 0, 1, 4, 8, 12) [Other] (1)Subject's diary (each day during the test period) |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Oral ingestion of the test products containing 150mg mushroom mycelium powder (2 grains x 1 times per a day; 12 weeks) | |
| Interventions/Control_2 | Oral ingestion of the control products not containing mushroom emycelium powder (2 grains x 1 times per a day; 12 weeks) | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | [1]Japanese males and females aged 40-64 years
[2]Individuals who are healthy and are not received treatment of disease [3]Individuals who feel tired by a physical labor [4]Individuals who serve a five-day work week (from Monday to Friday) and whose working hours are over 40 hours per a week [5]Individuals whose written informed consent has been obtained [6]Individuals who can come to the designated venue for this study and be inspected [7]Individuals judged appropriate for the study by the principal |
|||
| Key exclusion criteria | [1]Individuals using medical products
[2]Individuals who have a history of psychiatric disease, sleep disorder, high blood pressure, diabetes, and hyperlipidemia [3]Individuals who take medicine in the past 1 month to remedy disease [4]Individuals who have a history of serious hepatopathy, kidney damage, heart disease and hematological disease [5]Individuals who is a patient or have a history of or endocrine disease [6]Individuals whose BMI is over 30kg/m2 [7]Individuals who donated blood over 200mL in the past 1 month or over 400mL in the past 3 months [8]Individuals with serious anemia [9]Individuals who are sensitive to test product or other foods, and medical products [10]Individuals who are or are possibly, or are lactating [11]Individuals who excessively take alcohol (expressed in an amount of alcohol: over 60mg/day) [12]Individuals whose life style will change during the test period (ex. a night shift, travel for a long time, job transfer) [13]Individuals who had a habit to ingest health-promoting foods, foods for specified health uses, health foods, or supplements in the past 3 month or will ingest those foods during the test period [14]Individuals who participated in other clinical studies in the past 3 months [15]Individuals judged inappropriate for the study by the principal |
|||
| Target sample size | 64 | |||
| Research contact person | |
| Name of lead principal investigator | Mitsuhiro Sugimoto |
| Organization | Otsubokai Medical Corporation Tohto Bunkyo Hospital |
| Division name | Head |
| Address | 3-5-7 Yushima Bunkyo-ku Tokyo 113-0034, JAPAN |
| TEL | 03-3831-2181 |
| info@tes-h.co.jp | |
| Public contact | |
| Name of contact person | Toshiyasu Tamura |
| Organization | TES Holdings Co., Ltd. |
| Division name | Department of Clinical Trial |
| Address | 6F University of Tokyo Entrepreneur Plaza 7-3-1 Hongo Bunkyo-ku Tokyo 113-0033, JAPAN |
| TEL | 03-6801-8480 |
| Homepage URL | |
| info@tes-h.co.jp | |
| Sponsor | |
| Institute | RCT Japan Inc. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Golden Biotechnology Corp. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026301 |